Dr  Lucy Murtha

Dr Lucy Murtha

Postdoctoral Research Fellow

School of Medicine and Public Health

Career Summary

Biography

Dr Murtha is a Postdoctoral Research Scholar in the School of Medicine and Public Health at the University of Newcastle. Dr Murtha’s current research interests involve understanding the molecular mechanisms of cardiac fibrosis, a devastating consequence of almost every cardiac disease, of which treatment options are inadequate. She is interested in using pre-clinical models of cardiovascular disease to find effective ways of reversing the devastating effects heart scarring.

Dr Murtha completed a Bachelor of Biomedical Science (Honours) and a Doctor of Philosophy (PhD) at the University of Newcastle, Australia. Her PhD thesis investigated the mechanisms causing pressure to rise in the skull (intracranial pressure) following experimental stroke and the benefits of using therapeutic body cooling (hypothermia) to prevent this dangerous rise in pressure. The data collected throughout her PhD changed the current understanding of intracranial pressure regulation after stroke and the use of short-term hypothermia as a therapy. Dr Murtha is closely involved with further preclinical and clinical investigations which are currently underway.

Dr Murtha was recently awarded the Australian Government’s prestigious, competitive, merit-based Endeavour fellowship, which provided the opportunity to visit and collaborate with a world-leading laboratory at the University of Toronto, Canada. She was also awarded the Australian Society for Medical Research International award to collaborate with the world-leading cardiovascular institute, the Centro Nacional de Investigaciones Cardiovasculares (CNIC) in Spain.

Dr Murtha’s PhD was generously supported by an Emlyn and Jennie Thomas Postgraduate Medical Research Scholarship. The provision of this scholarship allowed her to travel to the University of Glasgow, UK, to conduct an international collaborative project for 12 months. This project resulted in the fascinating discovery that the major cause of the elevated pressure after stroke was not due to brain swelling, as was previously assumed, and lead a high impact journal article which went on to win the Best Research Higher Degree Publication of the Month, and of the Year by the School of Biomedical Sciences and Pharmacy, and the Faculty of Health and Medicine, respectively at the RHD Excellence Awards, 2015. Dr Murtha’s PhD thesis abstract was nominated by the University of Newcastle to be published in the Journal and Proceedings of the Royal Society of New South Wales. 


Qualifications

  • PhD, University of Newcastle
  • Bachelor of Biomedical Sciences, University of Newcastle
  • Bachelor of Biomedical Sciences (Hons), University of Newcastle

Keywords

  • Biomedical Sciences - Cardiology
  • Biomedical Sciences - Neuroscience
  • Cardiac Fibrosis
  • Cardiovascular Disease
  • Extracellular Matrix
  • Heart Failure
  • Intracranial Pressure
  • Ischaemic Stroke
  • Left Ventricular Remodelling
  • Medical Physiology
  • Oedema (cerebral)
  • Pre-clinical Models of Cardiovascular Disease
  • Therapeutic Hypothermia

Fields of Research

Code Description Percentage
310910 Animal physiology - systems 25
320101 Cardiology (incl. cardiovascular diseases) 75

Professional Experience

UON Appointment

Title Organisation / Department
Postdoctoral Research Fellow University of Newcastle
School of Medicine and Public Health
Australia

Academic appointment

Dates Title Organisation / Department
20/4/2015 - 4/4/2016 Postdoctoral Researcher Discipline of Human Physiology, School of Biomedical Sciences and Pharmacy, Faculty of health and Medicine, University of Newcastle
Australia
Edit

Publications

For publications that are currently unpublished or in-press, details are shown in italics.


Journal article (22 outputs)

Year Citation Altmetrics Link
2024 Croft AJ, Kelly C, Chen D, Haw TJ, Murtha LA, Balachandran L, et al., 'Sex-based differences in short and longer-term diet-induced metabolic heart disease.', Am J Physiol Heart Circ Physiol, (2024) [C1]
DOI 10.1152/ajpheart.00467.2023
Co-authors Andrew Boyle, Tattjhong Haw
2023 Murtha LA, Hardy SA, Mabotuwana NS, Bigland MJ, Bailey T, Raguram K, et al., 'Fibulin-3 is necessary to prevent cardiac rupture following myocardial infarction', Scientific Reports, 13 (2023) [C1]

Despite the high prevalence of heart failure in the western world, there are few effective treatments. Fibulin-3 is a protein involved in extracellular matrix (ECM) structural int... [more]

Despite the high prevalence of heart failure in the western world, there are few effective treatments. Fibulin-3 is a protein involved in extracellular matrix (ECM) structural integrity, however its role in the heart is unknown. We have demonstrated, using single cell RNA-seq, that fibulin-3 was highly expressed in quiescent murine cardiac fibroblasts, with expression highest prior to injury and late post-infarct (from ~ day-28 to week-8). In humans, fibulin-3 was upregulated in left ventricular tissue and plasma of heart failure patients. Fibulin-3 knockout (Efemp1 -/-) and wildtype mice were subjected to experimental myocardial infarction. Fibulin-3 deletion resulted in significantly higher rate of cardiac rupture days 3¿6 post-infarct, indicating a weak and poorly formed scar, with severe ventricular remodelling in surviving mice at day-28 post-infarct. Fibulin-3 knockout mice demonstrated less collagen deposition at day-3 post-infarct, with abnormal collagen fibre-alignment. RNA-seq on day-3 infarct tissue revealed upregulation of ECM degradation and inflammatory genes, but downregulation of ECM assembly/structure/organisation genes in fibulin-3 knockout mice. GSEA pathway analysis showed enrichment of inflammatory pathways and a depletion of ECM organisation pathways. Fibulin-3 originates from cardiac fibroblasts, is upregulated in human heart failure, and is necessary for correct ECM organisation/structural integrity of fibrotic tissue to prevent cardiac rupture post-infarct.

DOI 10.1038/s41598-023-41894-9
Co-authors Andrew Boyle, Aaron Sverdlov, Doan Ngo
2023 Hardy SA, Liesinger L, Patrick R, Poettler M, Rech L, Gindlhuber J, et al., 'Extracellular Matrix Protein-1 as a Mediator of Inflammation-Induced Fibrosis After Myocardial Infarction', JACC: Basic to Translational Science, 8 1539-1554 (2023) [C1]
DOI 10.1016/j.jacbts.2023.05.010
Co-authors Andrew Boyle
2022 Sharma P, Beck D, Murtha LA, Figtree G, Boyle A, Gentile C, 'Fibulin-3 Deficiency Protects Against Myocardial Injury Following Ischaemia/Reperfusion in in vitro Cardiac Spheroids', FRONTIERS IN CARDIOVASCULAR MEDICINE, 9 (2022) [C1]
DOI 10.3389/fcvm.2022.913156
Citations Scopus - 4
Co-authors Andrew Boyle
2022 Mabotuwana NS, Rech L, Lim J, Hardy SA, Murtha LA, Rainer PP, Boyle AJ, 'Paracrine Factors Released by Stem Cells of Mesenchymal Origin and their Effects in Cardiovascular Disease: A Systematic Review of Pre-clinical Studies', STEM CELL REVIEWS AND REPORTS, 18 2606-2628 (2022) [C1]
DOI 10.1007/s12015-022-10429-6
Citations Scopus - 16Web of Science - 10
Co-authors Andrew Boyle
2019 Murtha L, Morten M, Schuliga M, Mabotuwana N, Hardy S, Waters D, et al., 'The Role of Pathological Aging in Cardiac and Pulmonary Fibrosis', Aging and Disease, 10 419-428 (2019) [C1]
DOI 10.14336/AD.2018.0601
Citations Scopus - 49Web of Science - 36
Co-authors Michael Schuliga, Aaron Sverdlov, Andrew Boyle
2019 Hardy SA, Mabotuwana NS, Murtha LA, Coulter B, Sanchez-Bezanilla S, Al-Omary MS, et al., 'Novel role of extracellular matrix protein 1 (ECM1) in cardiac aging and myocardial infarction', PLoS ONE, 14 (2019) [C1]

Introduction The prevalence of heart failure increases in the aging population and following myocardial infarction (MI), yet the extracellular matrix (ECM) remodeling underpinning... [more]

Introduction The prevalence of heart failure increases in the aging population and following myocardial infarction (MI), yet the extracellular matrix (ECM) remodeling underpinning the development of aging- and MI-associated cardiac fibrosis remains poorly understood. A link between inflammation and fibrosis in the heart has long been appreciated, but has mechanistically remained undefined. We investigated the expression of a novel protein, extracellular matrix protein 1 (ECM1) in the aging and infarcted heart. Methods Young adult (3-month old) and aging (18-month old) C57BL/6 mice were assessed. Young mice were subjected to left anterior descending artery-ligation to induce MI, or transverse aortic constriction (TAC) surgery to induce pressure-overload cardiomyopathy. Left ventricle (LV) tissue was collected early and late post-MI/TAC. Bone marrow cells (BMCs) were isolated from young healthy mice, and subject to flow cytometry. Human cardiac fibroblast (CFb), myocyte, and coronary artery endothelial & smooth muscle cell lines were cultured; human CFbs were treated with recombinant ECM1. Primary mouse CFbs were cultured and treated with recombinant angiotensin-II or TGF-ß1. Immunoblotting, qPCR and mRNA fluorescent in-situ hybridization (mRNA-FISH) were conducted on LV tissue and cells. Results ECM1 expression was upregulated in the aging LV, and in the infarct zone of the LV early post-MI. No significant differences in ECM1 expression were found late post-MI or at any time-point post-TAC. ECM1 was not expressed in any resident cardiac cells, but ECM1 was highly expressed in BMCs, with high ECM1 expression in granulocytes. Flow cytometry of bone marrow revealed ECM1 expression in large granular leucocytes. mRNA-FISH revealed that ECM1 was indeed expressed by inflammatory cells in the infarct zone at day-3 post-MI. ECM1 stimulation of CFbs induced ERK1/2 and AKT activation and collagen-I expression, suggesting a pro-fibrotic role. Conclusions ECM1 expression is increased in ageing and infarcted hearts but is not expressed by resident cardiac cells. Instead it is expressed by bone marrow-derived granulocytes. ECM1 is sufficient to induce cardiac fibroblast stimulation in vitro. Our findings suggest ECM1 is released from infiltrating inflammatory cells, which leads to cardiac fibroblast stimulation and fibrosis in aging and MI. ECM1 may be a novel intermediary between inflammation and fibrosis.

DOI 10.1371/journal.pone.0212230
Citations Scopus - 25Web of Science - 17
Co-authors Andrew Boyle
2017 Rostas JAP, Hoffman A, Murtha LA, Pepperall D, McLeod DD, Dickson PW, et al., 'Ischaemia- and excitotoxicity-induced CaMKII-Mediated neuronal cell death: The relative roles of CaMKII autophosphorylation at T286 and T253', Neurochemistry International, 104 6-10 (2017) [C1]

Ischaemia/excitotoxicity produces persistent activation of CaMKII (Ca2+-calmodulin stimulated protein kinase II) that initiates cell death. This study investigated the involvement... [more]

Ischaemia/excitotoxicity produces persistent activation of CaMKII (Ca2+-calmodulin stimulated protein kinase II) that initiates cell death. This study investigated the involvement of CaMKII phosphorylation at T286 and T253 in producing this persistent activation. In T286A-aCaMKII transgenic mice that lack the ability to phosphorylate aCaMKII at T286, transient occlusion of the middle cerebral artery for 90¿min resulted in no significant difference in infarct size compared to normal littermate controls. Overexpression of the phospho-mimic mutant T286D-aCaMKII in differentiated neuroblastoma cell lines did not enhance excitotoxicity-induced cell death compared to overexpression of wild type aCaMKII. By contrast, overexpression of the phospho-mimic mutant T253D-aCaMKII significantly enhanced excitotoxicity-induced cell death whereas overexpression of the phospho-null mutant T253V-aCaMKII produced no enhancement. These results indicate that T286 phosphorylation does not play a significant role in ischaemia/excitotoxicity induced CaMKII-mediated cell death and suggest that T253 phosphorylation is required to produce the persistent activation of CaMKII involved in ischaemia/excitotoxicity induced cell death.

DOI 10.1016/j.neuint.2017.01.002
Citations Scopus - 19Web of Science - 15
Co-authors Damian Mcleod, Phil Dickson, Kathryn Skelding, John Rostas, Neil Spratt
2017 Murtha LA, Schuliga MJ, Mabotuwana NS, Hardy SA, Waters DW, Burgess JK, et al., 'The processes and mechanisms of cardiac and pulmonary fibrosis', Frontiers in Physiology, 8 1-15 (2017) [C1]
DOI 10.3389/fphys.2017.00777
Citations Scopus - 141Web of Science - 107
Co-authors Andrew Boyle, Michael Schuliga
2016 Murtha LA, 'The effects and mechanisms of the therapeutic hypothermia on intracranial pressure regulation following ischaemic stroke in rats', Journal and Proceedings of the Royal Society of New South Wales, 149 101-102 (2016)
2016 Beard DJ, Murtha LA, McLeod DD, Spratt NJ, 'Intracranial Pressure and Collateral Blood Flow', Stroke, 47 1695-1700 (2016) [C1]
DOI 10.1161/STROKEAHA.115.011147
Citations Scopus - 21Web of Science - 14
Co-authors Neil Spratt, Daniel J Beard, Damian Mcleod
2016 Beard DJ, Logan CL, McLeod DD, Hood RJ, Pepperall D, Murtha LA, Spratt NJ, 'Ischemic penumbra as a trigger for intracranial pressure rise - A potential cause for collateral failure and infarct progression?', J Cereb Blood Flow Metab, 36 917-927 (2016) [C1]
DOI 10.1177/0271678X15625578
Citations Scopus - 16Web of Science - 14
Co-authors Rebecca Hood, Neil Spratt, Daniel J Beard, Damian Mcleod
2016 Murtha LA, Beard DJ, Bourke JT, Pepperall D, McLeod DD, Spratt NJ, 'Intracranial Pressure Elevation 24 h after Ischemic Stroke in Aged Rats Is Prevented by Early, Short Hypothermia Treatment.', Front Aging Neurosci, 8 124 (2016) [C1]
DOI 10.3389/fnagi.2016.00124
Citations Scopus - 18Web of Science - 15
Co-authors Daniel J Beard, Neil Spratt, Damian Mcleod
2015 Murtha LA, McLeod DD, Pepperall D, McCann SK, Beard DJ, Tomkins AJ, et al., 'Intracranial pressure elevation after ischemic stroke in rats: Cerebral edema is not the only cause, and short-duration mild hypothermia is a highly effective preventive therapy', Journal of Cerebral Blood Flow and Metabolism, 35 592-600 (2015) [C1]

In both the human and animal literature, it has largely been assumed that edema is the primary cause of intracranial pressure (ICP) elevation after stroke and that more edema equa... [more]

In both the human and animal literature, it has largely been assumed that edema is the primary cause of intracranial pressure (ICP) elevation after stroke and that more edema equates to higher ICP. We recently demonstrated a dramatic ICP elevation 24 hours after small ischemic strokes in rats, with minimal edema. This ICP elevation was completely prevented by short-duration moderate hypothermia soon after stroke. Here, our aims were to determine the importance of edema in ICP elevation after stroke and whether mild hypothermia could prevent the ICP rise. Experimental stroke was performed in rats. ICP was monitored and short-duration mild (35 °C) or moderate (32.5 °C) hypothermia, or normothermia (37 °C) was induced after stroke onset. Edema was measured in three studies, using wet-dry weight calculations, T 2-weighted magnetic resonance imaging, or histology. ICP increased 24 hours after stroke onset in all normothermic animals. Short-duration mild or moderate hypothermia prevented this rise. No correlation was seen between ¿ICP and edema or infarct volumes. Calculated rates of edema growth were orders of magnitude less than normal cerebrospinal fluid production rates. These data challenge current concepts and suggest that factors other than cerebral edema are the primary cause of the ICP elevation 24 hours after stroke onset.

DOI 10.1038/jcbfm.2014.230
Citations Scopus - 39Web of Science - 35
Co-authors Damian Mcleod, Daniel J Beard, Neil Spratt
2015 Beard DJ, Mcleod DD, Logan CL, Murtha LA, Imtiaz MS, Van Helden DF, Spratt NJ, 'Intracranial pressure elevation reduces flow through collateral vessels and the penetrating arterioles they supply. A possible explanation for 'collateral failure' and infarct expansion after ischemic stroke', Journal of Cerebral Blood Flow and Metabolism, 35 861-872 (2015) [C1]

Recent human imaging studies indicate that reduced blood flow through pial collateral vessels ('collateral failure') is associated with late infarct expansion despite st... [more]

Recent human imaging studies indicate that reduced blood flow through pial collateral vessels ('collateral failure') is associated with late infarct expansion despite stable arterial occlusion. The cause for 'collateral failure' is unknown. We recently showed that intracranial pressure (ICP) rises dramatically but transiently 24 hours after even minor experimental stroke. We hypothesized that ICP elevation would reduce collateral blood flow. First, we investigated the regulation of flow through collateral vessels and the penetrating arterioles arising from them during stroke reperfusion. Wistar rats were subjected to intraluminal middle cerebral artery (MCA) occlusion (MCAo). Individual pial collateral and associated penetrating arteriole blood flow was quantified using fluorescent microspheres. Baseline bidirectional flow changed to MCA-directed flow and increased by >450% immediately after MCAo. Collateral diameter changed minimally. Second, we determined the effect of ICP elevation on collateral and watershed penetrating arteriole flow. Intracranial pressure was artificially raised in stepwise increments during MCAo. The ICP increase was strongly correlated with collateral and penetrating arteriole flow reductions. Changes in collateral flow post-stroke appear to be primarily driven by the pressure drop across the collateral vessel, not vessel diameter. The ICP elevation reduces cerebral perfusion pressure and collateral flow, and is the possible explanation for 'collateral failure' in stroke-in-progression.

DOI 10.1038/jcbfm.2015.2
Citations Scopus - 46Web of Science - 40
Co-authors Damian Mcleod, Neil Spratt, Daniel J Beard, Dirk Vanhelden
2015 Mcleod DD, Parsons MW, Hood R, Hiles B, Allen J, Mccann SK, et al., 'Perfusion computed tomography thresholds defining ischemic penumbra and infarct core: Studies in a rat stroke model', International Journal of Stroke, 10 553-559 (2015) [C1]

Background: Perfusion computed tomography is becoming more widely used as a clinical imaging tool to predict potentially salvageable tissue (ischemic penumbra) after ischemic stro... [more]

Background: Perfusion computed tomography is becoming more widely used as a clinical imaging tool to predict potentially salvageable tissue (ischemic penumbra) after ischemic stroke and guide reperfusion therapies. Aims: The study aims to determine whether there are important changes in perfusion computed tomography thresholds defining ischemic penumbra and infarct core over time following stroke. Methods: Permanent middle cerebral artery occlusion was performed in adult outbred Wistar rats (n=6) and serial perfusion computed tomography scans were taken every 30 mins for 2h. To define infarction thresholds at 1h and 2h post-stroke, separate groups of rats underwent 1h (n=6) and 2h (n=6) of middle cerebral artery occlusion followed by reperfusion. Infarct volumes were defined by histology at 24h. Co-registration with perfusion computed tomography maps (cerebral blood flow, cerebral blood volume, and mean transit time) permitted pixel-based analysis of thresholds defining infarction, using receiver operating characteristic curves. Results: Relative cerebral blood flow was the perfusion computed tomography parameter that most accurately predicted penumbra (area under the curve=0·698) and also infarct core (area under the curve=0·750). A relative cerebral blood flow threshold of <75% of mean contralateral cerebral blood flow most accurately predicted penumbral tissue at 0·5h (area under the curve=0·660), 1h (area under the curve=0·659), 1·5h (area under the curve=0·636), and 2h (area under the curve=0·664) after stroke onset. A relative cerebral blood flow threshold of <55% of mean contralateral most accurately predicted infarct core at 1h (area under the curve=0·765) and at 2h (area under the curve=0·689) after middle cerebral artery occlusion. Conclusions: The data provide perfusion computed tomography defined relative cerebral blood flow thresholds for infarct core and ischemic penumbra within the first two hours after experimental stroke in rats. These thresholds were shown to be stable to define the volume of infarct core and penumbra within this time window.

DOI 10.1111/ijs.12147
Citations Scopus - 16Web of Science - 14
Co-authors Christopher Levi, Neil Spratt, Rebecca Hood, Damian Mcleod, Mark Parsons
2015 Tomkins AJ, Schleicher N, Murtha L, Kaps M, Levi CR, Nedelmann M, Spratt NJ, 'Platelet rich clots are resistant to lysis by thrombolytic therapy in a rat model of embolic stroke', Experimental and Translational Stroke Medicine, 7 (2015) [C1]

Background: Early recanalization of occluded vessels in stroke is closely associated with improved clinical outcome. Microbubble-enhanced sonothrombolysis is a promising therapy t... [more]

Background: Early recanalization of occluded vessels in stroke is closely associated with improved clinical outcome. Microbubble-enhanced sonothrombolysis is a promising therapy to improve recanalization rates and reduce the time to recanalization. Testing any thrombolytic therapy requires a model of thromboembolic stroke, but to date these models have been highly variable with regards to clot stability. Here, we developed a model of thromboembolic stroke in rats with site-specific delivery of platelet-rich clots (PRC) to the main stem of the middle cerebral artery (MCA). This model was used in a subsequent study to test microbubble-enhanced sonothrombolysis. Methods: In Study 1 we investigated spontaneous recanalization rates of PRC in vivo over 4 hours and measured infarct volumes at 24 hours. In Study 2 we investigated tPA-mediated thrombolysis and microbubble-enhanced sonothrombolysis in this model. Results: Study 1 demonstrated stable occlusion out to 4 hours in 5 of 7 rats. Two rats spontaneously recanalized at 40 and 70 minutes post-embolism. Infarct volumes were not significantly different in recanalized rats, 43.93 ± 15.44% of the ischemic hemisphere, compared to 48.93 ± 3.9% in non-recanalized animals (p = 0.7). In Study 2, recanalization was not observed in any of the groups post-treatment. Conclusions: Site specific delivery of platelet rich clots to the MCA origin resulted in high rates of MCA occlusion, low rates of spontaneous clot lysis and large infarction. These platelet rich clots were highly resistant to tPA with or without microbubble-enhanced sonothrombolysis. This resistance of platelet rich clots to enhanced thrombolysis may explain recanalization failures clinically and should be an impetus to better clot-type identification and alternative recanalization methods.

DOI 10.1186/s13231-014-0014-y
Citations Scopus - 52
Co-authors Neil Spratt, Christopher Levi
2014 Beard DJ, McLeod DD, Murtha LA, Spratt NJ, 'Elevation of intracranial pressure reduces leptomeningeal collateral and watershed blood flow during experimental stroke', CEREBROVASCULAR DISEASES, 37 65-65 (2014)
Co-authors Daniel J Beard, Damian Mcleod, Neil Spratt
2014 Murtha LA, McLeod DD, Beard DJ, Pepperall DG, Spratt NJ, 'Short duration mild hypothermia prevents delayed intracranial pressure rise following experimental ischaemic stroke', CEREBROVASCULAR DISEASES, 37 340-340 (2014)
Co-authors Neil Spratt, Damian Mcleod, Daniel J Beard
2014 Murtha LA, Mcleod DD, Mccann SK, Pepperall D, Chung S, Levi CR, et al., 'Short-duration hypothermia after ischemic stroke prevents delayed intracranial pressure rise', International Journal of Stroke, 9 553-559 (2014) [C1]

Background: Intracranial pressure elevation, peaking three to seven post-stroke is well recognized following large strokes. Data following small-moderate stroke are limited. Thera... [more]

Background: Intracranial pressure elevation, peaking three to seven post-stroke is well recognized following large strokes. Data following small-moderate stroke are limited. Therapeutic hypothermia improves outcome after cardiac arrest, is strongly neuroprotective in experimental stroke, and is under clinical trial in stroke. Hypothermia lowers elevated intracranial pressure; however, rebound intracranial pressure elevation and neurological deterioration may occur during rewarming. Hypotheses: (1) Intracranial pressure increases 24h after moderate and small strokes. (2) Short-duration hypothermia-rewarming, instituted before intracranial pressure elevation, prevents this 24h intracranial pressure elevation. Methods: Long-Evans rats with two hour middle cerebral artery occlusion or outbred Wistar rats with three hour middle cerebral artery occlusion had intracranial pressure measured at baseline and 24h. Wistars were randomized to 2·5h hypothermia (32·5°C) or normothermia, commencing 1h after stroke. Results: In Long-Evans rats (n=5), intracranial pressure increased from 10·9±4·6mmHg at baseline to 32·4±11·4mmHg at 24h, infarct volume was 84·3±15·9mm3. In normothermic Wistars (n=10), intracranial pressure increased from 6·7±2·3mmHg to 31·6±9·3mmHg, infarct volume was 31·3±18·4mm3. In hypothermia-treated Wistars (n=10), 24h intracranial pressure did not increase (7·0±2·8mmHg, P<0·001 vs. normothermia), and infarct volume was smaller (15·4±11·8mm3, P<0·05). Conclusions: We saw major intracranial pressure elevation 24h after stroke in two rat strains, even after small strokes. Short-duration hypothermia prevented the intracranial pressure rise, an effect sustained for at least 18h after rewarming. The findings have potentially important implications for design of future clinical trials. © 2013 The Authors. International Journal of Stroke © 2013 World Stroke Organization.

DOI 10.1111/ijs.12181
Citations Scopus - 29Web of Science - 25
Co-authors Christopher Levi, Neil Spratt, Damian Mcleod
2014 Murtha LA, Yang Q, Parsons MW, Levi CR, Beard DJ, Spratt NJ, McLeod DD, 'Cerebrospinal fluid is drained primarily via the spinal canal and olfactory route in young and aged spontaneously hypertensive rats', Fluids and Barriers of the CNS, 11 (2014) [C1]

Background: Many aspects of CSF dynamics are poorly understood due to the difficulties involved in quantification and visualization. In particular, there is debate surrounding the... [more]

Background: Many aspects of CSF dynamics are poorly understood due to the difficulties involved in quantification and visualization. In particular, there is debate surrounding the route of CSF drainage. Our aim was to quantify CSF flow, volume, and drainage route dynamics in vivo in young and aged spontaneously hypertensive rats (SHR) using a novel contrast-enhanced computed tomography (CT) method.Methods: ICP was recorded in young (2-5 months) and aged (16 months) SHR. Contrast was administered into the lateral ventricles bilaterally and sequential CT imaging was used to visualize the entire intracranial CSF system and CSF drainage routes. A customized contrast decay software module was used to quantify CSF flow at multiple locations.Results: ICP was significantly higher in aged rats than in young rats (11.52 ± 2.36 mmHg, versus 7.04 ± 2.89 mmHg, p = 0.03). Contrast was observed throughout the entire intracranial CSF system and was seen to enter the spinal canal and cross the cribriform plate into the olfactory mucosa within 9.1 ± 6.1 and 22.2 ± 7.1 minutes, respectively. No contrast was observed adjacent to the sagittal sinus. There were no significant differences between young and aged rats in either contrast distribution times or CSF flow rates. Mean flow rates (combined young and aged) were 3.0 ± 1.5 µL/min at the cerebral aqueduct; 3.5 ± 1.4 µL/min at the 3rd ventric= and 2.8 ± 0.9 µL/min at the 4th ventricle. Intracranial CSF volumes (and as percentage total brain volume) were 204 ± 97 µL (8.8 ± 4.3%) in the young and 275 ± 35 µL (10.8 ± 1.9%) in the aged animals (NS).Conclusions: We have demonstrated a contrast-enhanced CT technique for measuring and visualising CSF dynamics in vivo. These results indicate substantial drainage of CSF via spinal and olfactory routes, but there was little evidence of drainage via sagittal sinus arachnoid granulations in either young or aged animals. The data suggests that spinal and olfactory routes are the primary routes of CSF drainage and that sagittal sinus arachnoid granulations play a minor role, even in aged rats with higher ICP. © 2014 Murtha et al.; licensee BioMed Central Ltd.

DOI 10.1186/2045-8118-11-12
Citations Scopus - 88Web of Science - 65
Co-authors Neil Spratt, Daniel J Beard, Damian Mcleod, Mark Parsons, Christopher Levi
2012 Murtha L, McLeod D, Spratt N, 'Epidural intracranial pressure measurement in rats using a fiber-optic pressure transducer.', Journal of visualized experiments : JoVE, (2012) [C1]
Citations Scopus - 32Web of Science - 23
Co-authors Neil Spratt, Damian Mcleod
Show 19 more journal articles

Conference (16 outputs)

Year Citation Altmetrics Link
2023 Mabotuwana NS, Skerrett-Byrne DA, Ashour DE, Butel-Simoes L, Mcgee M, Rech L, et al., 'Harnessing novel paracrine factors from the proteomes of cardiac and mesenchymal stem cells to promote repair of the fibrotic heart', EUROPEAN JOURNAL OF HEART FAILURE (2023)
Co-authors Matt Dun, Andrew Boyle, David Skerrett-Byrne
2021 Croft AJ, Kelly C, Chen D, Murtha L, Sugito S, Boyle A, et al., 'Adipose-targeted overexpression of mitochondrial-targeted catalase does not improve cardio-metabolic parameters in mice with diet-induced obesity', EUROPEAN HEART JOURNAL (2021)
Co-authors Andrew Boyle, Aaron Sverdlov
2020 Mabotuwana NSNS, Byrne DS, Butel-Simoes L, Mcgee M, Smith ND, Almazi JG, et al., 'Harnessing the proteome of human cardiac stem cells to identify unique paracrine factors that may promote cardiac regeneration in heart failure', EUROPEAN JOURNAL OF HEART FAILURE (2020)
Co-authors Andrew Boyle, Matt Dun
2019 Hardy S, Mabotuwana NS, Murtha LA, Coulter B, Bezenilla SS, Al-Omary MS, et al., 'The role of extracellular matrix protein 1 (ECM1) - a novel link between inflammation and cardiac fibrosis', EUROPEAN HEART JOURNAL, Paris, FRANCE (2019)
Co-authors Andrew Boyle
2018 Murtha LA, Mabotuwana NS, Hardy SA, Boyle AJ, 'Fibulin-3 Plays a Key Role in the Formation of Infarct-Induced Cardiac Fibrosis', CIRCULATION (2018)
Co-authors Andrew Boyle
2018 Brown Y, Jamaluddin MFB, Ghosh A, Mellick AS, Murtha L, Boyle A, Tanwar PS, 'The Glue of Cancer Cell Life: Characterization of the Acellular Component of High Grade Serous Ovarian Cancer Identifies Potential Novel Drug Targets', ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY (2018)
Co-authors Muhammad Jamaluddin, Arnab Ghosh, Pradeep Tanwar
2017 Kovacs T, Murtha L, Beard D, McLeod D, Hood R, Garcia-Esperon C, et al., 'A potential cause of early neurological deterioration after mild-moderate ischaemic stroke - raised intracranial pressure at 24 hours', INTERNATIONAL JOURNAL OF STROKE (2017)
Citations Web of Science - 1
Co-authors Daniel J Beard, Damian Mcleod, Christopher Levi, Rebecca Hood, Carlos Garciaesperon, Neil Spratt
2017 Murtha LA, Mabotuwana NR, Hardy SA, Boyle AJ, 'Fibulin-3 as a Potential Therapeutic Target for Cardiac Fibrosis', JOURNAL OF CARDIAC FAILURE, Dallas, TX (2017)
DOI 10.1016/j.cardfail.2017.07.071
Citations Web of Science - 1
Co-authors Andrew Boyle
2017 Murtha LA, Mabotuwana NS, Hardy SA, Boyle AJ, 'Fibulin-3 Plays a Key Role in Cardiac Fibrosis Following Myocardial Infarction in Mice', CIRCULATION, Anaheim, CA (2017)
Citations Web of Science - 1
Co-authors Andrew Boyle
2016 McLeod DD, Murtha LA, Beard DJ, Hood RJ, Logan CL, Pepperall D, Spratt NJ, 'Elevated intracranial pressure following stroke: there's more to the story than cerebral oedema.', JOURNAL OF CEREBRAL BLOOD FLOW AND METABOLISM, Vancouver, CANADA (2016)
Co-authors Damian Mcleod, Daniel J Beard, Neil Spratt, Rebecca Hood
2016 Beard DJ, Logan CL, McLeod DD, Hood RJ, Pepperall D, Murtha LA, Spratt NJ, 'MIDDLE CEREBRAL ARTERY OCCLUSION WITH GOOD COLLATERALS CAUSES EARLY INTRACRANIAL PRESSURE ELEVATION POST STROKE', JOURNAL OF CEREBRAL BLOOD FLOW AND METABOLISM, Vancouver, CANADA (2016)
Co-authors Rebecca Hood, Neil Spratt, Daniel J Beard, Damian Mcleod
2015 Rostas J, Hoffman A, Murtha L, Pepperall D, McLeod D, Dickson P, et al., 'Ischaemia-induced neuronal cell death is mediated by molecular targeting of CaMKII phosphorylated at T253', JOURNAL OF NEUROCHEMISTRY, Cairns, AUSTRALIA (2015) [E3]
Co-authors John Rostas, Phil Dickson, Damian Mcleod, Neil Spratt, Kathryn Skelding
2013 McLeod D, Murtha L, Burke J, Pitsillides K, 'Biotelemetry of intracranial pressure in freely moving rats: a detailed description of surgical implantation for chronic studies', FASEB JOURNAL, MA, Boston (2013)
Co-authors Damian Mcleod
2012 Murtha LA, McLeod DD, Spratt NJ, 'The effects of therapeutic hypothermia on intracranial pressure after experimental ischemic stroke', Abstracts. Australian Neuroscience Society 32nd Annual Meeting, Gold Coast, Queensland (2012) [E3]
Co-authors Damian Mcleod, Neil Spratt
2012 McLeod DD, Murtha LA, Pitsillides K, 'A new method of attaching a solid-state pressure sensor for measurement of chronic intracranial pressure in freely moving rats using biotelemetry', FASEB Journal, San Diego, CA (2012) [E3]
Co-authors Damian Mcleod
2011 Murtha LA, McLeod DD, McCann S, Pepperall D-G, Spratt NJ, 'Short duration hypothermia results in sustained prevention of intracranial pressure elevation following experimental stroke', International Journal of Stroke, Adelaide, SA (2011) [E3]
Co-authors Damian Mcleod, Neil Spratt
Show 13 more conferences

Other (1 outputs)

Year Citation Altmetrics Link
2015 Murtha LA, Mcleod DD, Pepperall D, Mccann SK, Beard DJ, Tomkins AJ, et al., 'Erratum: Intracranial pressure elevation after ischemic stroke in rats: Cerebral edema is not the only cause, and short-duration mild hypothermia is a highly effective preventive therapy (Journal of Cerebral Blood Flow & Metabolism (2015) 35 (592-600) DOI: 10.1038/jcbfm.2014.230)', ( issue.12 pp.2109) (2015) [O1]
DOI 10.1038/jcbfm.2015.209
Citations Scopus - 8Web of Science - 9
Co-authors Neil Spratt, Daniel J Beard, Damian Mcleod
Edit

Grants and Funding

Summary

Number of grants 17
Total funding $906,684

Click on a grant title below to expand the full details for that specific grant.


20231 grants / $25,000

NSW Cardiovascular Research Network Career Advancement Grant$25,000

Funding body: National Heart Foundation of Australia

Funding body National Heart Foundation of Australia
Project Team Doctor Lucy Murtha
Scheme NSW Cardiovascular Research Network (CVRN) Career Advancement Grant
Role Lead
Funding Start 2023
Funding Finish 2023
GNo G2300843
Type Of Funding C1700 - Aust Competitive - Other
Category 1700
UON Y

20222 grants / $234,516

Identifying a novel therapy for cardiac fibrosis$224,032

Funding body: Hunter Medical Research Institute

Funding body Hunter Medical Research Institute
Project Team Professor Andrew Boyle, Doctor Lucy Murtha
Scheme Research Grant
Role Investigator
Funding Start 2022
Funding Finish 2024
GNo G2200302
Type Of Funding C3300 – Aust Philanthropy
Category 3300
UON Y

Murine wound healing assay to test novel anti-fibrotic compounds$10,484

Funding body: Hunter New England Local Health District

Funding body Hunter New England Local Health District
Project Team Doctor Lucy Murtha, Professor Andrew Boyle
Scheme John Hunter Hospital Charitable Trust Grant
Role Lead
Funding Start 2022
Funding Finish 2022
GNo G2200385
Type Of Funding C2400 – Aust StateTerritoryLocal – Other
Category 2400
UON Y

20211 grants / $18,182

Developing a new test for a novel protein involved in heart scarring$18,182

Funding body: Hunter New England Local Health District

Funding body Hunter New England Local Health District
Project Team Doctor Lucy Murtha, Professor Andrew Boyle
Scheme John Hunter Hospital Charitable Trust Grant
Role Lead
Funding Start 2021
Funding Finish 2021
GNo G2100244
Type Of Funding C2400 – Aust StateTerritoryLocal – Other
Category 2400
UON Y

20191 grants / $53,672

The Applied Biosystems QuantStudio 6 Flex Real-Time PCR System$53,672

Funding body: NHMRC (National Health & Medical Research Council)

Funding body NHMRC (National Health & Medical Research Council)
Project Team Professor Kirsty Pringle, Professor Simon Keely, Doctor Hannah Palliser, Doctor Jonathan Paul, Doctor Marina Paul, Doctor Lucy Murtha
Scheme Equipment Grant
Role Investigator
Funding Start 2019
Funding Finish 2019
GNo G1900306
Type Of Funding Scheme excluded from IGS
Category EXCL
UON Y

20181 grants / $25,000

Determining the mechanisms of myocardial infarction induced cardiac fibrosis: what role does fibulin-3 play?$25,000

Funding body: Hunter Medical Research Institute

Funding body Hunter Medical Research Institute
Project Team Doctor Lucy Murtha, Professor Andrew Boyle, Professor Doan Ngo, Professor Aaron Sverdlov
Scheme Project Grant
Role Lead
Funding Start 2018
Funding Finish 2018
GNo G1801370
Type Of Funding C3300 – Aust Philanthropy
Category 3300
UON Y

20175 grants / $171,250

Characterising the role of Fibulin-3 in health and disease$96,750

Funding body: Hunter Medical Research Institute

Funding body Hunter Medical Research Institute
Project Team Doctor Lucy Murtha, Professor Andrew Boyle
Scheme Project Grant
Role Lead
Funding Start 2017
Funding Finish 2021
GNo G1700327
Type Of Funding C3300 – Aust Philanthropy
Category 3300
UON Y

Determining the mechanisms of cardiac fibrosis$25,000

Funding body: Hunter Medical Research Institute

Funding body Hunter Medical Research Institute
Project Team Doctor Lucy Murtha
Scheme Greaves Family Early Career Support Grant
Role Lead
Funding Start 2017
Funding Finish 2017
GNo G1700352
Type Of Funding C3300 – Aust Philanthropy
Category 3300
UON Y

Endeavour Research Fellowship$24,500

Funding body: Department of Education and Training

Funding body Department of Education and Training
Scheme Endeavour Research Fellowship
Role Lead
Funding Start 2017
Funding Finish 2017
GNo
Type Of Funding Aust Competitive - Commonwealth
Category 1CS
UON N

Identifying the role of fibulin-3 in cardiac fibrosis$20,000

Funding body: Hunter Medical Research Institute

Funding body Hunter Medical Research Institute
Project Team Doctor Lucy Murtha, Dr Rohan Bhagwandeen, Dr Rachel Hatton
Scheme Project Grant
Role Lead
Funding Start 2017
Funding Finish 2017
GNo G1700475
Type Of Funding C3200 – Aust Not-for Profit
Category 3200
UON Y

ASMR Travel Grant$5,000

Funding body: Australian Society for Medical Research (ASMR)

Funding body Australian Society for Medical Research (ASMR)
Scheme International Travel Grant
Role Lead
Funding Start 2017
Funding Finish 2017
GNo
Type Of Funding Grant - Aust Non Government
Category 3AFG
UON N

20161 grants / $4,000

Characterising the role of fibulin-3 in health and disease$4,000

Funding body: UON, Faculty Health and Medicine

Funding body UON, Faculty Health and Medicine
Scheme Faculty Health and Medicine
Role Lead
Funding Start 2016
Funding Finish 2016
GNo
Type Of Funding Internal
Category INTE
UON N

20155 grants / $375,064

A new understanding of increased pressure within the skull in brain diseases$300,000

Funding body: Brain Foundation (NSW Branch)

Funding body Brain Foundation (NSW Branch)
Project Team Professor Neil Spratt, Doctor Damian McLeod, Doctor Lucy Murtha, Doctor Daniel Beard
Scheme Major Research Gift Initiative
Role Investigator
Funding Start 2015
Funding Finish 2017
GNo G1501106
Type Of Funding C3200 – Aust Not-for Profit
Category 3200
UON Y

Stroke In Progression: a new understanding of pathophysiology opening the door to effective therapy$25,222

Funding body: John Hunter Hospital Charitable Trust

Funding body John Hunter Hospital Charitable Trust
Project Team Doctor Ferdinand Miteff, Doctor Damian McLeod, Doctor Daniel Beard, Doctor Lucy Murtha, Professor Neil Spratt
Scheme Research Grant
Role Investigator
Funding Start 2015
Funding Finish 2015
GNo G1500830
Type Of Funding Other Public Sector - State
Category 2OPS
UON Y

Cooling the blood to prevent raised intracranial pressure and improve outcome after stroke$19,842

Funding body: National Stroke Foundation

Funding body National Stroke Foundation
Project Team Doctor Lucy Murtha, Professor Neil Spratt
Scheme Research Grant
Role Lead
Funding Start 2015
Funding Finish 2015
GNo G1500591
Type Of Funding Grant - Aust Non Government
Category 3AFG
UON Y

A better understanding of intracranial pressure changes after brain injury$15,000

Funding body: Hunter Medical Research Institute

Funding body Hunter Medical Research Institute
Project Team Professor Neil Spratt, Doctor Damian McLeod, Doctor Lucy Murtha, Doctor Daniel Beard
Scheme Research Grant
Role Investigator
Funding Start 2015
Funding Finish 2017
GNo G1500709
Type Of Funding Grant - Aust Non Government
Category 3AFG
UON Y

A better understanding of intracranial pressure changes after brain injury$15,000

Funding body: Hunter Medical Research Institute

Funding body Hunter Medical Research Institute
Project Team

Doctor Neil Spratt

Scheme Research Grant
Role Investigator
Funding Start 2015
Funding Finish 2015
GNo
Type Of Funding Grant - Aust Non Government
Category 3AFG
UON N
Edit

Research Supervision

Number of supervisions

Completed1
Current1

Current Supervision

Commenced Level of Study Research Title Program Supervisor Type
2020 PhD The Origin of Extracellular Matrix Protein 1 (ECM) Production in Cardiac Ageing and Myocardial Infarction PhD (Medicine), College of Health, Medicine and Wellbeing, The University of Newcastle Co-Supervisor

Past Supervision

Year Level of Study Research Title Program Supervisor Type
2024 PhD The Identification of Novel Paracrine Factors Expressed by Human Stem Cells of Mesenchymal Origin to Develop Regenerative Non-Cellular Therapies for Cardiac Fibrosis PhD (Medicine), College of Health, Medicine and Wellbeing, The University of Newcastle Co-Supervisor
Edit

Dr Lucy Murtha

Position

Postdoctoral Research Fellow
School of Medicine and Public Health
College of Health, Medicine and Wellbeing

Contact Details

Email lucy.murtha@newcastle.edu.au
Phone (02) 4042 0411
Link Research Networks

Office

Room HMRI Level 3 East
Building Hunter Medical Research Institute
Edit